XOMA Licensees to Present Significant Clinical Data at 2021 ASCO Annual Meeting
May 21 2021 - 8:00AM
XOMA Corporation (Nasdaq: XOMA) recently learned its licensees are
presenting at the upcoming 2021 American Society of Clinical
Oncology (ASCO) Annual Meeting, which is being held June 4-8,
2021, in a virtual setting.
“We congratulate Novartis and AVEO on their recent announcements
regarding NIS793 and ficlatuzumab, respectively. We were
particularly excited to see the statements each company made in
their May 19th press releases regarding the potential for advancing
these drug candidates to Phase 3 clinical programs. We look
forward to each company’s data presentations at ASCO early next
month,” stated Jim Neal, Chief Executive Officer at XOMA. “We
wish both companies continued success with their development
activities.”
Novartis1
Title: Phase Ib study of the anti-TGF-β
monoclonal antibody (mAb) NIS793 combined with spartalizumab
(PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid
tumors Abstract: 2509; poster sessionDate
and Time: June 4, 2021, at 9:00 a.m. Eastern Time
Title: Phase II study of the anti-TGF-β
monoclonal antibody (mAb) NIS793 with and without the PD-1
inhibitor spartalizumab in combination with
nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts)
with first-line metastatic pancreatic ductal adenocarcinoma
(mPDAC)2.Abstract: TPS4173
AVEO Oncology3
Title: Randomized Phase II trial of
ficlatuzumab with or without cetuximab in pan-refractory, advanced
head and neck squamous cell carcinoma
(HNSCC).Presenter: Julie E. Bauman, M.D.,
MPH, Professor of Medicine, Chief, Division of
Hematology/Oncology, Associate Director of Translational
Research, University of Arizona Cancer
CenterAbstract: 6015Date and
Time: June 4, 2021 at 9:00 a.m. Eastern
Time
NIS793 and ficlatuzumab are investigational compounds.
Efficacy and safety have not been established in either drug
candidate. There is no guarantee that NIS793 and/or
ficlatuzumab will become commercially available.
About XOMA Corporation XOMA has built a
significant portfolio of products that are licensed to and being
developed by other biotech and pharmaceutical companies. The
Company’s portfolio of partner-funded programs spans multiple
stages of the drug development process and across various
therapeutic areas. Many of these licenses are the result of
XOMA’s pioneering efforts in the discovery and development of
antibody therapeutics. The Company’s royalty-aggregator
business model includes acquiring additional milestone and royalty
rights associated with drug development programs with third-party
funding. For more information, visit www.xoma.com.
______________________________1
https://www.novartis.com/news/media-releases/novartis-unveil-new-data-asco-and-eha-from-its-robust-portfolio-including-overall-survival-prostate-and-breast-cancer2
https://meetinglibrary.asco.org/record/201247/abstract3
http://investor.aveooncology.com/news-releases/news-release-details/aveo-oncology-announces-positive-results-randomized-phase-2
Safe Harbor Statement Certain statements
contained in this press release are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, including
statements regarding the potential of XOMA’s portfolio of partnered
programs and licensed technologies generating substantial milestone
and royalty proceeds over time, creating additional value for the
stockholders, cash sufficiency forecast, economic outlook, and
potential impact of the COVID-19 pandemic. These statements
are based on assumptions that may not prove accurate, and actual
results could differ materially from those anticipated due to
certain risks inherent in the biotechnology industry, including
those related to the fact that our product candidates subject to
out-license agreements are still being developed, and our licensees
may require substantial funds to continue development which may not
be available; we do not know whether there will be, or will
continue to be, a viable market for the products in which we have
an ownership or royalty interest; if the therapeutic product
candidates to which we have a royalty interest do not receive
regulatory approval, our third-party licensees will not be able to
market them, and the impact to the global economy as a result of
the COVID-19 pandemic. Other potential risks to XOMA meeting
these expectations are described in more detail in XOMA's most
recent filing on Form 10-K and in other SEC filings. Consider
such risks carefully when considering XOMA's prospects. Any
forward-looking statement in this press release represents XOMA's
views only as of the date of this press release and should not be
relied upon as representing its views as of any subsequent
date. XOMA disclaims any obligation to update any forward-
looking statement, except as required by applicable law.
EXPLANATORY NOTE: Any references to “portfolio” in this press
release refer strictly to milestone and/or royalty rights
associated with a basket of drug products in development. Any
references to “assets” in this press release refer strictly to
milestone and/or royalty rights associated with individual drug
products in development. References to royalties or royalty
rates strictly refer to future potential payment streams regardless
of whether or not they are technically defined as royalties in the
underlying contractual agreement; further, any rates referenced
herein are subject to potential future contractual adjustments.
As of the date of this press release, all assets in XOMA’s
milestone and royalty portfolio are investigational
compounds. Efficacy and safety have not been
established. There is no guarantee that any of these assets
will become commercially available.
Investor contacts: |
|
Gitanjali Jain |
Juliane Snowden |
Solebury Trout |
XOMA |
+1-646-378-2949 |
+1-646-438-9754 |
gogawa@soleburytrout.com |
juliane.snowden@xoma.com |
|
|
|
|
|
|
Media contact: |
|
Kathy Vincent |
|
KV Consulting & Management |
|
+1-310-403-8951 |
|
kathy@kathyvincent.com |
|
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024